CARNITINE: A ROLE IN THE HUMAN ORGANISM AND THE POSSIBILITIES OF THERAPEUTIC USE IN VARIOUS DISEASES

Download full text PDF
Issue: 
3
Year: 
2017

I. Khoroshilov, MD I.I. Mechnikov North-Western State Medical University, Saint Petersburg

The paper discusses the possibilities of therapeutic use of L-carnitine (Elkar®) in cardiovascular, liver and kidney diseases, male infertility, Alzheimer’s disease, cachexia, and obesity, in sports medicine.
Keywords: 
carnitine
role in the body
therapeutic use
malnutrition
obesity
atherosclerosis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Luft R., Ikkos D., Palmieri G. et al. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical and morphological study // J. Clin. Invest. – 1962; 41: 1776–804.
  2. Pola P., Tondi P., dal Lago A. et al. Statistical evaluation of long-term L-carnitine therapy in hyperlipoproteinemias // Drugs Exp. Clin. Res. – 1983; 9: 925–34.
  3. Dinicolantonio J., Niazi A., McCarty M. et al. L-carnitine for the treatment of acute myocardial infarction // Rev. Cardiovasc. Med. – 2014; 15 (1): 52–62.
  4. Semigolovskij N.Ju., Vertsinskij E.K., Azanov B.A. i dr. Polozhitel'nye inotropnye svojstva L-karnitina pri sindrome malogo vybrosa u bol'nyh ostrym infarktom miokarda // Kardiologija i serdechno-sosudistaja hirurgija. – 2013; 3: 43–6.
  5. Glezer M.G., Kiseleva A.E., Astashkin E.I. Vlijanie L-karnitina na ChSS i QT u patsientov s ostrym koronarnym sindromom // Serdtse. – 2015; 14: 78–84.
  6. Lee B., Lin J., Lin Y. et al Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients // Nutrition. – 2015; 31 (3): 475–9.
  7. Leont'eva I.V. Narushenie kletochnoj energetiki pri patologii miokarda. Primenenie L-karnitina / M.: Medpraktika-M, 2009; 52 s.
  8. Silverio R., Laviano A., Fanelli F. et al. L-carnitine and cancer cachexia: clinical and experimental aspects // J. Cachexia, sarcopenia, muscle. – 2011; 2 (1): 37–44.
  9. Madeddu C., Dessi M., Panzone F. et al. Randomized phase III Clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome // Clin. Nutr. – 2012; 31 (2): 176–82.
  10. Gramignano G., Lusso M., Madeddu C. et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy // Nutrition. – 2006; 22: 136–45.
  11. Graziano F., Bisonni R., Catalano V. et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients // Br. J. Cancer. – 2002; 86: 1854–7.
  12. Cruciani R., Dvorkin E., Homel P. et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis // Ann. NY Acad. Sci. – 2004; 1033: 168–76.
  13. Cruciani R., Dvorkin E., Homel P. et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study // J. Pain Symptom Manage. – 2006; 32: 551–9.
  14. Higuchi T., Abe M., Yamazaki T. et al. Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial // Nutrients. – 2014; 6 (12): 5992–6004.
  15. Fukuda S., Koyama H., Kondo K. et al. Effects of nutritional supplementation on fatigue, and autonomic and immune dysfunction in patients with end-stage renal disease: a randomized, double-blind, placebo-controlled, multicenter trial // PLoS One. – 2015; 10: e0119578.
  16. Guarnieri G. Carnitine in maintenance hemodialysis patients // J. Ren. Nutr. – 2015; 25 (2): 169–75.
  17. Chen Y., Abbate M., Tang L. et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis // Am. J. Clin. Nutr. – 2014; 99 (2): 408–22.
  18. Vidot H., Carey S., Allman-Farinelli M. et al. Systematic review: the treatment of muscle cramps in patients with cirrhosis // Aliment. Pharmacol. Ther. – 2014; 40 (3): 221–32.
  19. Bonafé L., Berger M., Que Y. et al. Carnitine deficiency in chronic critical illness // Curr. Opin. Clin. Nutr. Metab. Care. – 2014; 17 (2): 200–9.
  20. Puskarich M., Finkel M., Karnovsky A. et al. Pharmacometabolomics of L-carnitine treatment response phenotypes in patients with septic shock // Ann. Am. Thorac. Soc. – 2015; 12 (1): 46–56.
  21. von Haehling S., Anker S. Treatment of cachexia: An overview of recent developments // Int. J. Cardiol. – 2015; 184: 736–42.
  22. Derosa G., Cicero A., Gaddi A. et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus // Clin. Ther. – 2003; 25: 1429–39.
  23. Molfino A., Cascino A., Conte C. et al. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism // JPEN. – 2010; 34: 295–9.
  24. Dambrova M., Liepinsh E. Risks and benefits of carnitine supplementation in diabetes // Exp. Clin. Endocrinol. Diabetes. – 2015; 123 (2): 95–100.
  25. Rauschert S., Uhl O., Koletzko B. et al. Metabolomic biomarkers for obesity in humans: a short review // Ann. Nutr. Metab. – 2014; 64 (3–4): 314–24.
  26. Zhang J., Wu Z., Cai Y. et al. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study // Nutrition. – 2014; 26 (13): 110.
  27. Bene J., Komlosi K., Gasztonyi B. et al. Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet // World J. Gastroenterol. – 2005; 11: 6671–5.
  28. Horoshilov I.E. Kaheksija i istoschenie: patogenez, diagnostika i lechenie // Klinicheskoe pitanie. – 2007; 3: 51–4.
  29. Costa M., Canale D., Filicori M. et al. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Italyan Study Group on Carnitine and Male Infertility // Andrologia. – 1994; 26: 155–9.
  30. Shang X., Wang L., Mo D. Effect and safety of L-carnitine in the treatment of idiopathic oligoasthenozoospermia: a systemic review // Zhonghua Nan Ke Xue. – 2015; 21 (1): 65–73.
  31. Kopelevich V.M. Chudo karnitina / M.: Genezis, 2003; 80 s.
  32. Horoshilov I.E., Panov P.B. Klinicheskaja nutritsiologija: uch. posobie. Pod red. A.V.Shabrova / SPb: ELBI-SPb, 2009; 284 s.
  33. Kępka A., Chojnowska S., Okungbowa O. et al. The role of carnitine in the perinatal period // Dev. Period. Med. – 2014; 18 (4): 417–25.
  34. De Sousa C., Chalmers R., Stacey T. et al. The response to L-carnitine and glycine therapy in isovaleric academia // Eur. J. Pediatr. – 1986; 144: 451–6.
  35. Roe C., Bohan T. L-carnitine therapy in propionicacidaemia // Lancet. – 1982; 1: 1411–2.
  36. Seccombe D., James L., Booth F. L-carnitine treatment in glutaric aciduria type 1 // Neurology. – 1986; 36: 264–7.
  37. Brin I.L., Neudahin E.V., Dunajkin M.L. Karnitin v pediatrii: issledovanija i klinicheskaja praktika / M.: Medpraktika-M, 2015; 112 s.
  38. Suhorukov V.S. Lechenie i profilaktika energodefitsitnyh sostojanij s primeneniem preparata El'kar / M., 2007; 16 s.
  39. Nikolaeva E.A., Harabadze M.N., Zolkina I.V. i dr. Nedostatochnost' karnitina u detej s nasledstvennymi boleznjami obmena veschestv i mitohondrial'nymi zabolevanijami: osobennosti patogeneza i effektivnost' lechenija // Pediatrija. – 2013; 3: 42–8.
  40. Bowman B. Acetyl-L-carnitine and Alzheimer’s disease // Nutr. Rev. – 1992; 50: 142–4.
  41. Calvani M., Carta A., Caruso G. et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer’s disease // Ann. NY Acad. Sci. – 1992; 663: 483–6.
  42. Salvioly G., Neri M. L-acetylcarnitine treatment of mental decline in the elderly // Drugs Exp. Clin. Res. – 1994; 20: 169–76.
  43. Wang S., Han C., Lee S. et al. A review of current evidence for acetyl-l-carnitine in the treatment of depression // J. Psychiatr. Res. – 2014; 53: 30–7.
  44. De Falco F., D’Angelo E., Grimaldi G. et al. Effect of acetyl-L-carnitine in Down’s syndrome // Clin. Ter. – 1994; 144: 123–7 [Italian].
  45. Arnold L., Amato A., Bozzolo H. et al. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multisite, Placebo-controlled pilot trial // J. Child Adolesc. Psychopharmacol. – 2007; 17: 791–802.
  46. Radzhabkadiev R.M., Korosteleva M.M., Evstratova V.S. i dr. L-karnitin: svojstva i perspektivy primenenija v sportivnoj praktike // Voprosy pitanija. – 2015; 84: 4–11.
  47. Lekarstva i BAD v sporte: prakticheskoe rukovodstvo dlja sportivnyh vrachej, trenerov i sportsmenov. Pod red. R.D. Sejfully, Z.G. Ordzhonikidze / M.: Litera, 2003; 320 s.
  48. Parastaev S.A., Topol'skij A.V., Hvan D.E. i dr. O rezul'tatah primenenija L-karnitina (preparat El'kar) u sportsmenov vysokoj kvalifikatsii // Sportivnaja meditsina: nauka i praktika. – 2012; 2: 21–8.
  49. Dragan G., Vasiliu D., Georgescu E. et al. Studies concerning chronic and acute effects of L-carnitine on some biological parameters in elite athletes // Physiologie. – 1987; 24: 2–28.
  50. Balykova L.A., Ivjanskij S.A., Schekina N.V. i dr. Itogi i perspektivy metabolicheskoj korrektsii stress-oposredovannyh narushenij v detskom sporte preparatom El'kar // Sportivnaja meditsina: nauka i praktika. – 2014; 1: 1–8.
  51. Balykova L.A., Ivjanskij S.A., Urzjaeva A.N. i dr. El'kar v detskoj sportivnoj praktike // Ros. vestn. perinatol. i pediat. – 2013; 5: 102–8.
  52. Katz D., Friedman R. Nutrition in clinical practice. 2nd ed. / Philadelphia etc.: Lippincott Willams and Wilkins, 2008; 570 p.
  53. Wang Z., Klipfell E., Benneth B. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease // Nature. – 2011; 472: 57–63.
  54. Koeth R., Wang Z., Levison B. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis // Nat. Med. – 2013; 19 (5): 576–85.
  55. Tang W., Hazen S. The contributory role of gut microbiota in cardiovascular disease // J Clin. Invest. – 2014; 124 (10): 4204–11.
  56. Ussher J., Lopaschuk G., Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk // Atherosclerosis. – 2013; 231 (2): 456–61.
  57. Johri A., Heyland D., Hétu M. et al. Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies // Nutr. Metab. Cardiovasc. Dis. – 2014; 24 (8): 808–14.
  58. Ferguson J. Meat-loving microbes: do steak-eating bacteria promote atherosclerosis? // Circ. Cardiovasc. Genet. – 2013; 6: 308–9.
  59. Kashuh E.A., Ivashkin V.T. Probiotiki, metabolizm i funktsional'noe sostojanie serdechno-sosudistoj sistemy // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2016; 1: 8–14.